Salman H. Shukri-Al

Saint Petersburg, SPE, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Infection of the lower urinary tract: new possibilities of herbal medicine

Infection of the lower urinary tract: new possibilities of herbal medicine

Journal: Urologiia (Moscow, Russia : 1999)

Published: April 29, 2022

Antiadhesive strategy for non-antibacterial prophylaxis of recurrent lower urinary tract infections

Antiadhesive strategy for non-antibacterial prophylaxis of recurrent lower urinary tract infections

Journal: Urologiia (Moscow, Russia : 1999)

Published: July 12, 2021

Recurrent lower urinary tract infection in women: treatment and prevention

Recurrent lower urinary tract infection in women: treatment and prevention

Journal: Urologiia (Moscow, Russia : 1999)

Published: December 30, 2020

D-mannose for prevention and treatment of lower urinary tract infection: pathogenetic basics and clinical results

D-mannose for prevention and treatment of lower urinary tract infection: pathogenetic basics and clinical results

Journal: Urologiia (Moscow, Russia : 1999)

Published: September 08, 2020

Imidafenacin for treatment of overactive bladder and urgent urinary incontinence: the results of open-label multicenter randomized controlled clinical trial

Imidafenacin for treatment of overactive bladder and urgent urinary incontinence: the results of open-label multicenter randomized controlled clinical trial

Journal: Urologiia (Moscow, Russia : 1999)

Published: February 12, 2019

Fosfomycin for treatment of uncomplicated lower urinary tract infection

Fosfomycin for treatment of uncomplicated lower urinary tract infection

Journal: Urologiia (Moscow, Russia : 1999)

Published: December 22, 2018

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.

Journal: Neurourology and urodynamics

Published: August 30, 2018

Novel Approach for Endoscopic Management of Duodenal Injury during Perirenal Infected Haematoma Drainage after Shock-Wave Lithotripsy.

Novel Approach for Endoscopic Management of Duodenal Injury during Perirenal Infected Haematoma Drainage after Shock-Wave Lithotripsy.

Journal: Case reports in urology

Published: March 20, 2018

Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).

Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).

Journal: European urology

Published: January 17, 2018

Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.

Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.

Journal: Urology

Published: February 15, 2017

Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].

Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].

Journal: The Journal of urology

Published: March 19, 2016

Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.

Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.

Journal: Clinical genitourinary cancer

Published: February 17, 2016

Showing 1-12 of 15

Last Updated: 09/26/2026